Abstract
AbstractIntroductionBreast cancer, especially triple-negative breast cancer (TNBC), is a significant concern in the US, being the most common cancer among women and the second leading cause of cancer-related deaths. TNBC lacks crucial receptors targeted in other breast cancer types, leading to a poor prognosis and limited treatment options due to its aggressive and heterogeneous nature.SignificanceAfrican American women (AAW) with TNBC face higher mortality rates and more aggressive disease compared to Caucasian American women (CAW). Despite efforts to find biomarkers specific to AAW and CAW with TNBC, limited sample availability and data resources have been obstacles.MethodsIn our study, we examined 237 candidate peptide biomarkers using publicly available data.Resultsidentify 23 unique prognostic biomarkers. These biomarkers accurately assess patient conditions based on race-specific gene expression patterns, holding potential to address racial disparities in TNBC treatment.ConclusionOverall, our research sheds light on how racial genetic profiles influence TNBC prognosis and treatment efficacy. The identified prognostic biomarkers pave the way for future studies addressing TNBC racial disparities and personalized treatment approaches.
Publisher
Cold Spring Harbor Laboratory